The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
127096741 12709674 1 I 2005 20160822 20160902 20160902 EXP BE-HQ SPECIALTY-BE-2016INT000862 INTERCHEM SZTURZ P, SPECENIER P, VAN LAER C, VAN DEN WEYNGAERT D, CORTHOUTS B, CARP L, ET AL.. LONG-TERM REMISSION OF LOCALLY RECURRENT OROPHARYNGEAL CANCER AFTER DOCETAXEL-BASED CHEMOTHERAPY PLUS CETUXIMAB. EUR ARCH OTORHINOLARYNGOL. 2015;273 (6):1629-1636. 57.00 YR M Y 0.00000 20160902 OT BE BE

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
127096741 12709674 1 PS CISPLATIN. CISPLATIN 1 100 MG, PER SQUARE METER OF BODY-SURFACE AREA ON DAY 1 WEEKLY Y 18057 100 MG/M**2
127096741 12709674 2 SS CISPLATIN. CISPLATIN 1 75 MG, PER SQUARE METER ON DAY 1 WEEKLY Y 18057 75 MG/M**2
127096741 12709674 3 SS 5-FLUOROURACIL FLUOROURACIL 1 1000 MG, PER SQUARE METER ON DAYS 1-4 WEEKLY Y 0 1000 MG/M**2
127096741 12709674 4 SS 5-FLUOROURACIL FLUOROURACIL 1 750 MG, PER SQUARE METER ON DAYS 1-5 WEEKLY Y 0 750 MG/M**2
127096741 12709674 5 SS CETUXIMAB CETUXIMAB 1 400 MG, PER SQUARE METER WEEKLY (INITIAL DOSE) Y 0 400 MG/M**2
127096741 12709674 6 SS CETUXIMAB CETUXIMAB 1 250 MG, PER SQUARE METER WEEKLY Y 0 250 MG/M**2
127096741 12709674 7 SS CETUXIMAB CETUXIMAB 1 400 MG, PER SQUARE METER ON DAY 1 OF THE FIRST CYCLE (INITIAL LOADING DOSE) Y 0 400 MG/M**2
127096741 12709674 8 SS CETUXIMAB CETUXIMAB 1 250 MG, PER SQAUARE METER ON DAYS 1, 8, AND 15 WEEKLY Y 0 250 MG/M**2
127096741 12709674 9 SS DOCETAXEL. DOCETAXEL 1 75 MG, PER SQUARE METER ON DAY 1 WEEKLY Y 0 75 MG

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
127096741 12709674 1 Oropharyngeal cancer
127096741 12709674 3 Oropharyngeal cancer
127096741 12709674 5 Oropharyngeal cancer
127096741 12709674 9 Oropharyngeal cancer

Outcome of event

Event ID CASEID OUTC COD
127096741 12709674 OT
127096741 12709674 LT

Reactions reported

Event ID CASEID DRUG REC ACT PT
127096741 12709674 Alopecia
127096741 12709674 Constipation
127096741 12709674 Deafness
127096741 12709674 Decreased appetite
127096741 12709674 Diarrhoea
127096741 12709674 Dizziness
127096741 12709674 Fatigue
127096741 12709674 Febrile neutropenia
127096741 12709674 Infection
127096741 12709674 Nail disorder
127096741 12709674 Nausea
127096741 12709674 Peripheral sensory neuropathy
127096741 12709674 Rash
127096741 12709674 Stomatitis

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
127096741 12709674 1 20050509 20050906 0
127096741 12709674 2 20060614 20060916 0
127096741 12709674 3 20050509 20050906 0
127096741 12709674 4 20060614 20060916 0
127096741 12709674 5 20050913 0
127096741 12709674 6 20060503 0
127096741 12709674 7 20060614 0
127096741 12709674 8 20060916 0
127096741 12709674 9 20060614 20060916 0